Journal of Physiology and Pharmacology 2007-09-01

BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice.

J Jawień, M Gajda, R Olszanecki, R Korbut

Index: J. Physiol. Pharmacol. 58(3) , 583-8, (2007)

Full Text: HTML

Abstract

Recently, we have shown that MK-886 - an inhibitor of five lipoxygenase activating protein (FLAP) inhibits atherosclerosis in apolipoprotein E / LDL receptor - double knockout mice. We, therefore, wanted to find out if other FLAP inhibitor - BAYx1005 given at a dose of 1.88 mg per 100 mg of body weight per day during 16 weeks, could also attenuate atherogenesis. In apoE/LDLR - DKO mouse model BAYx1005 inhibited atherogenesis, measured both by "en face" method (23.84 +/- 2.7% vs. 15.16 +/- 1.4%) and "cross-section" method (497236 +/- 31516 microm(2) vs. 278107 +/- 21824 microm(2)). This is the first report that shows the effect of BAYx1005 on atherogenesis in gene-targeted mice.

Related Compounds

  • BAY-X 1005

Related Articles:

Leukotriene modifiers in the treatment of asthma. Look promising across the board of asthma severity.

1998-04-25

[BMJ 316(7140) , 1257-8, (1998)]

Inhibition of 5-LO activating protein (FLAP) activity decreases proteinuria in streptozotocin (STZ)-induced diabetic rats.

2002-01-01

[Adv. Exp. Med. Biol. 507 , 79-83, (2002)]

Pharmacology of the 5-lipoxygenase inhibitors BAY Y 1015 and BAY X 1005 in the horse.

1999-09-09

[J. Vet. Pharmacol. Ther. 20(4) , 296-307, (1997)]

Potential anti-inflammatory effects of 5-lipoxygenase inhibition--exemplified by the leukotriene synthesis inhibitor BAY X 1005.

1997-12-01

[J. Physiol. Pharmacol. 48(4) , 529-36, (1997)]

Ineffective elimination of Leishmania major by inflammatory (MRP14-positive) subtype of monocytic cells.

2000-11-01

[Immunobiology 202(5) , 442-59, (2000)]

More Articles...